Skip to main content

Table 3 Association of TERTp and H/N/K-RAS mutations with clinicopathological featurs in 53 FTC patients

From: Mutation profiles of follicular thyroid tumors by targeted sequencing

Variations H/N/K-RAS- TERTp- H/N/K-RAS+ TERTp- H/N/K-RAS- TERTp+ H/N/K-RAS+ TERTp+ P
Cases 30 10 6 7  
Sex 0.406
 Male 8 (27) 2 (20) 2 (33) 4 (57)
 Female 22 (73) 8 (80) 4 (67) 3 (43)
Age, years 0.013
 Median ± SD 43 ± 3 33 ± 5 59 ± 2 66 ± 3
Tumor size (cm) 0.764
 <2.0 8 (27) 3 (30) 3 (50) 3 (43)
 2.0–4.0 16 (53) 5 (50) 1 (17) 3 (43)
 >4.0 6 (20) 2 (20) 2 (33) 1 (14)
Lymph node metastasis 0.271
 Yes 2 (7) 1 (10) 0 2 (29)
 No 28 (93) 9 (90) 6 (100) 5 (71)
Distant metastasis 0.057
 Yes 0 0 1 (17) 1 (14)
 No 30 (100) 10 (100) 5 (83) 6 (86)
AJCC Stage 0.015
 I 27 (90) 10 (100) 4 (67) 3 (43)
 II 3 (10) 0 2 (33) 2 (29)
 III 0 0 0 1 (14)
 IV 0 0 0 1 (14)
Histologic type 0.681
 Minimally invasive 16 (53) 5 (50) 2 (33) 2 (28)
 Encapsulated angioinvasive 7 (23) 4 (40) 2 (33) 2 (28)
 Widely invasive 7 (23) 1 (10) 2 (33) 3 (43)
Disease recurrence/persistence a 0.026
 Yes 2 (7) 1 (10) 2 (29) 3 (50)
 No 28 (93) 9 (90) 4 (71) 3 (50)
  1. a, fifty-two patients were available to evaluate the disease recurrence/persistence status, the other patient was lost to follow-up
  2. Abbreviations: TERTp, TERT promoter, FTC follicular thyroid carcinoma, AJCC American Joint Committee on Cancer, 8th edition staging, P P-value, median ± SD median ± standard deviation